Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2017 1
2019 1
2020 1
2021 2
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease.
Schmid P, Cortes J, Joaquim A, Jañez NM, Morales S, Díaz-Redondo T, Blau S, Neven P, Lemieux J, García-Sáenz JÁ, Hart L, Biyukov T, Baktash N, Massey D, Burris HA 3rd, Rugo HS. Schmid P, et al. Among authors: diaz redondo t. Breast Cancer Res. 2023 Jun 12;25(1):67. doi: 10.1186/s13058-023-01649-w. Breast Cancer Res. 2023. PMID: 37308971 Free PMC article. Clinical Trial.
Significant Decrease in Annual Cancer Diagnoses in Spain during the COVID-19 Pandemic: A Real-Data Study.
Ruiz-Medina S, Gil S, Jimenez B, Rodriguez-Brazzarola P, Diaz-Redondo T, Cazorla M, Muñoz-Ayllon M, Ramos I, Reyna C, Bermejo MJ, Godoy A, Torres E, Cobo M, Galvez L, Rueda A, Alba E, Ribelles N. Ruiz-Medina S, et al. Among authors: diaz redondo t. Cancers (Basel). 2021 Jun 28;13(13):3215. doi: 10.3390/cancers13133215. Cancers (Basel). 2021. PMID: 34203185 Free PMC article.
Machine learning and natural language processing (NLP) approach to predict early progression to first-line treatment in real-world hormone receptor-positive (HR+)/HER2-negative advanced breast cancer patients.
Ribelles N, Jerez JM, Rodriguez-Brazzarola P, Jimenez B, Diaz-Redondo T, Mesa H, Marquez A, Sanchez-Muñoz A, Pajares B, Carabantes F, Bermejo MJ, Villar E, Dominguez-Recio ME, Saez E, Galvez L, Godoy A, Franco L, Ruiz-Medina S, Lopez I, Alba E. Ribelles N, et al. Among authors: diaz redondo t. Eur J Cancer. 2021 Feb;144:224-231. doi: 10.1016/j.ejca.2020.11.030. Epub 2020 Dec 26. Eur J Cancer. 2021. PMID: 33373867
Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data.
Díaz-Redondo T, Lavado-Valenzuela R, Jimenez B, Pascual T, Gálvez F, Falcón A, Alamo MDC, Morales C, Amerigo M, Pascual J, Sanchez-Muñoz A, González-Guerrero M, Vicioso L, Laborda A, Ortega MV, Perez L, Fernandez-Martinez A, Chic N, Jerez JM, Alvarez M, Prat A, Ribelles N, Alba E. Díaz-Redondo T, et al. Front Oncol. 2019 Nov 5;9:1178. doi: 10.3389/fonc.2019.01178. eCollection 2019. Front Oncol. 2019. PMID: 31750258 Free PMC article.
[Teaching basic life support to the general population. Alumni intervention analysis].
Díaz-Castellanos MA, Fernández-Carmona A, Díaz-Redondo A, Cárdenas-Cruz A, García-del Moral R, Martín-Lopez J, Díaz-Redondo T. Díaz-Castellanos MA, et al. Among authors: diaz redondo t. Med Intensiva. 2014 Dec;38(9):550-7. doi: 10.1016/j.medin.2013.10.010. Epub 2014 Jan 31. Med Intensiva. 2014. PMID: 24485533 Free article. Spanish.